Yes, tianeptine is addictive. Although it was originally developed as an antidepressant and is still prescribed for depression in some countries, tianeptine activates the same brain receptors as opioid drugs. This means it can produce euphoria, trigger rapid tolerance, and cause a withdrawal syndrome nearly identical to opioid withdrawal. The FDA has never approved tianeptine for any medical use in the United States and has issued repeated warnings urging consumers not to purchase or use it.
Why Tianeptine Acts Like an Opioid
For years, tianeptine was thought to work through serotonin pathways, unlike any other antidepressant. That understanding changed when researchers screened it against a broad panel of human receptors and discovered it binds directly to the mu-opioid receptor, the same target activated by morphine, heroin, and prescription painkillers. A 2014 study published in Translational Psychiatry identified tianeptine as an effective mu-opioid receptor agonist, meaning it doesn’t just bind to the receptor but fully activates it.
This activation sets off a chain of events in the brain’s reward system. Tianeptine increases dopamine release in the nucleus accumbens, the region most associated with pleasure and reinforcement. That dopamine surge is what produces the brief euphoria some users describe and is the core mechanism behind why repeated use can become compulsive. In mouse studies, animals missing the mu-opioid receptor showed none of tianeptine’s rewarding, pain-relieving, or stimulating effects, confirming that receptor is the key driver.
How Quickly Tolerance Develops
One of the most concerning features of tianeptine is how fast the body adjusts to it. In controlled animal studies, tolerance to tianeptine’s pain-relieving effects began developing by day three of daily dosing and was statistically significant within a week. Tolerance to its stimulant-like effects on movement followed a similar pattern, building over the first few days and then declining sharply by day 11 to 15 of continuous use.
This rapid tolerance is what drives dose escalation in humans. In countries where tianeptine is prescribed, the standard therapeutic dose is 25 to 50 milligrams per day. But case reports paint a very different picture of recreational or compulsive use. One person started at the recommended 12.5 milligrams three times daily, began experiencing withdrawal between doses, and gradually increased to 100 milligrams every two hours. Another escalated to 150 milligrams three or four times a day chasing a brief wave of euphoria. At the extreme end, daily consumption can reach 3,000 milligrams, roughly 60 to 120 times the prescribed dose.
What Withdrawal Looks Like
Tianeptine withdrawal closely mirrors opioid withdrawal in both symptoms and severity. Reported symptoms include anxiety, depression, headaches, widespread muscle pain, restless legs, hot flashes, sweating, chills, abdominal cramping, nausea, diarrhea, vomiting, tremor, and rapid heart rate. Physical withdrawal symptoms typically last one to two weeks, though cravings can persist beyond that window. In at least one documented case, the patient reported being completely unable to work during the withdrawal period.
The combination of a short half-life (tianeptine is rapidly metabolized) and fast-developing tolerance means that people who use it frequently can begin experiencing withdrawal symptoms between doses surprisingly quickly. This creates a cycle where each dose provides shorter relief, pushing users to take more, more often.
How Tianeptine Addiction Is Treated
Because tianeptine addiction behaves so much like opioid addiction, clinicians have found success treating it with the same medications used for opioid use disorder. The most documented approach involves buprenorphine combined with naloxone (commonly known by brand names used in opioid treatment programs). In published case reports, this combination has helped patients stop tianeptine use and maintain abstinence after years of compulsive daily dosing. The clinical course of tianeptine addiction, including loss of control, functional impairment, tolerance, and withdrawal, matches the diagnostic criteria for opioid use disorder closely enough that the same treatment framework applies.
Legal Status and Availability
Tianeptine is not approved by the FDA for any purpose. It does not qualify as a dietary supplement or a food ingredient under U.S. law. Despite this, it has been widely sold online and in gas stations and convenience stores, marketed as a “nootropic” brain enhancer, a dietary supplement, or a “research chemical.” Products like Neptune’s Fix became particularly well known.
The scale of the problem has grown rapidly. Calls to U.S. poison control centers involving tianeptine rose from just 5 in 2014 to 83 in 2016, according to CDC data. By 2024, the FDA reported receiving severe adverse event reports linked to tianeptine products, including seizures, loss of consciousness, and deaths. In January 2024, the agency sent letters to convenience stores and gas stations urging them to pull tianeptine products from shelves. As of May 2025, the FDA’s warning covers all tianeptine products regardless of how they are labeled or marketed. Several states have passed their own bans, classifying tianeptine as a controlled substance.
If you encounter tianeptine sold as a supplement or cognitive enhancer, the packaging does not change the pharmacology. It activates opioid receptors, builds tolerance within days, and produces a withdrawal syndrome that can require medical management to safely navigate.